Techh.info/techtechnology hourly

Immunotherapy

headlines texts
19.03.2019
09:34 News-Medical.NetGARP protein can be a potential target for immunotherapy against colorectal cancer

Colorectal cancer is the third leading cause of cancer-related deaths in both men and women. Despite significant advances in therapies for this particular cancer, the five-year survival rate is 12 percent, according to the American Cancer Society.

Скрыть анонс
01:57 ScienceDaily.comThe story of GARP: A potential target for cancer immunotherapy

Researchers reveal how the cell surface receptor GARP plays a role in T regulatory cell function and migration to the gut. Because the presence of T regulatory cells in the gut is generally associated with negative outcomes in patients with colorectal cancer, GARP could have potential as a therapeutic target for patients with this type of cancer.

Скрыть анонс
18.03.2019
23:26 Technology.orgPreclinical Data Shows Combination Immunotherapy Could Stop Liver Cancer Growth

Even as overall cancer incidence and mortality decrease in the United States, the number of people diagnosed with

Скрыть анонс
15.03.2019
00:09 ScienceDaily.comHow immunotherapy may be effective for fighting tuberculosis

New research suggests that structures released by infected cells in tuberculosis may be used in tandem with antibiotics to boost the body's immune system, helping fight off the disease.

Скрыть анонс
14.03.2019
10:26 News-Medical.NetPreclinical data shows combination immunotherapy could suppress tumor growth in the liver

Even as overall cancer incidence and mortality decrease in the United States, the number of people diagnosed with liver cancer is on the rise.

Скрыть анонс
13.03.2019
23:23 ScienceDaily.comCombination immunotherapy could stop liver cancer growth

New preclinical data offers proof-of-principle for a combination immunotherapy that suppresses tumor growth in the liver. Current therapies for liver cancer are largely ineffective, resulting in poor outcomes.

Скрыть анонс
11.03.2019
11:40 News-Medical.NetPrecision cancer drugs spark powerful immune response and boost effects of immunotherapy

Precision cancer drugs called PARP inhibitors have a previously unknown ability to boost the immune system, and could help many more patients benefit from immunotherapy, a new study reveals.

Скрыть анонс
09.03.2019
18:08 ScienceDaily.comPrecision drugs could unmask cancers to immune system and boost effects of immunotherapy

Precision cancer drugs called PARP inhibitors have a previously unknown ability to boost the immune system, and could help many more patients benefit from immunotherapy, a new study reveals.

Скрыть анонс
01:56 CNN HealthFDA approves first immunotherapy regimen for breast cancer

The US Food and Drug Administration has granted its first approval to an immunotherapy regimen for breast cancer, the agency announced Friday.

Скрыть анонс
08.03.2019
22:00 Medscape.ComFDA Approves First Immunotherapy for Breast Cancer

For use in advanced triple-negative disease, atezolizumab is approved in combination with the chemotherapy nab-paclitaxel. The pairing improved progression-free survival.

Скрыть анонс
07.03.2019
13:06 News-Medical.NetACROBiosystems collaborates with ProMab Biotechnologies to develop immunotherapy products

ACROBiosystems, a leading manufacturer of recombinant proteins, announced that they have signed a collaboration agreement with ProMab Biotechnologies, a leading manufacturer of monoclonal antibodies and CAR-T cells.

Скрыть анонс
12:46 ClinicalOncology.comImmunotherapy Can Stall Without Supportive Care

Anaheim, Calif.—A young man came to Memorial Sloan Kettering Cancer Center (MSK) looking for help. He had tried multiple treatments for his acute lymphoblastic leukemia (ALL), but a bone marrow biopsy revealed his cancer had returned.

Скрыть анонс
06.03.2019
18:34 CancerNetwork.comTumor Mutational Burden to Guide Immunotherapy in Lung Cancer

A trial showed that tumor mutational burden may be effective as a biomarker in patients treated with immunotherapy.

Скрыть анонс
11:42 News-Medical.NetNuclear medicine imaging assesses melanoma patients' response to immunotherapy

Nuclear medicine imaging with PET/CT can monitor the effectiveness of immunotherapy treatment for metastatic melanoma and predict outcome. In this way, a patient's therapy can be more effectively tailored to his or her personal response.

Скрыть анонс
04.03.2019
04:10 CancerNetwork.comAdding a Vaccine to Immunotherapy in Lung Cancer: Will It Improve Outcomes?

Researchers studied the combination of a cellular vaccine known as HS-110 and nivolumab in an early-phase trial of patients with advanced non–small-cell lung cancer.

Скрыть анонс
28.02.2019
15:06 Technology.orgUsing anti-cancer immunotherapy to fight HIV

Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have shown that immunotherapy treatments against cancer could

Скрыть анонс
25.02.2019
18:56 ScienceDaily.comImmunotherapy for egg allergy may allow patients to eat egg safely long after treatment

After completing up to four years of egg oral immunotherapy (eOIT) treatment, certain participants were able to safely incorporate egg into their diet for five years.

Скрыть анонс
09:38 News-Medical.NetEgg oral immunotherapy could be safe way of desensitizing children, youth with egg allergy

UNC School of Medicine researcher Edwin Kim, MD, MS, says the results of a multi-year observational study are encouraging for those suffering from egg allergies.

Скрыть анонс
09:38 News-Medical.NetRegular dietary peanut consumption after immunotherapy may extend allergy treatment benefits

Regular dietary peanut consumption after completing oral immunotherapy or sublingual immunotherapy for peanut allergy may provide continued protection against accidental exposures to the allergen, according to a new study led by Edwin Kim, MD, who presented the findings at the annual American Academy of Allergy, Asthma and Immunology conference in San Francisco.

Скрыть анонс
20.02.2019
23:34 ScienceDaily.comNew machine learning technique rapidly analyzes nanomedicines for cancer immunotherapy

With their ability to treat a wide a variety of diseases, spherical nucleic acids (SNAs) are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components.

Скрыть анонс
22:09 FierceBiotech.comUsing Bristol-Myers’ popular leukemia drug to improve anti-PD-1 cancer immunotherapy

Because not all patients respond to anti-PD-1/L1 therapies, researchers are exploring new ways to improve their efficacy. Now, a team led by Cedars-Sinai Medical Center scientist has pinpointed Sprycel, a popular blood cancer drug by Bristol-Myers Squibb, as a potential booster.

Скрыть анонс
20:17 News-Medical.NetImmunotherapeutic antibody therapy to kill cancer has now progressed to patient testing

Developed by researchers at the University of Turku in Finland, an immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models.

Скрыть анонс
15:44 MedicalNewsToday.comMedical News Today: Aggressive brain cancer: Why does immunotherapy fail?

New research helps explain why some glioblastoma tumors respond to immunotherapy whereas the majority of these aggressive cancers do not.

Скрыть анонс
03:26 ScienceDaily.comBirch pollen allergen immunotherapy normalizes nasal gene-expression and microbial community

According to a new study, birch pollen allergen immunotherapy modifies the gene expression and microbiome profile of the nasal epithelium to correspond to those of healthy controls.

Скрыть анонс
19.02.2019
23:44 Nanowerk.comNew machine learning technique rapidly analyzes nanomedicines for cancer immunotherapy

Novel approach will aid scientists in optimizing SNAs as therapeutic vaccines to treat cancer.

Скрыть анонс
23:43 Phys.orgNew machine learning technique rapidly analyzes nanomedicines for cancer immunotherapy

Spherical nucleic acids are a class of personalized medicines for treating cancer and other diseasesSNAs are challenging to optimize because their structures can vary in many waysNorthwestern University team developed a library approach and machine learning to rapidly synthesize, analyze and select for potent SNA medicines

Скрыть анонс
21:27 News-Medical.NetAnti-cancer immunotherapy could be used to fight HIV

Researchers at the University of Montreal Hospital Research Centre have shown that immunotherapy treatments against cancer could reduce the amount of virus that persists in people on triple therapy.

Скрыть анонс
18.02.2019
11:07 News-Medical.NetCombination of PARP inhibitor and immunotherapy results in tumor regression in SCLC mouse models

Researchers at The University of Texas MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair achieved significant tumor regression in mouse models of small cell lung cancer, suggesting a promising new approach for treating patients with this aggressive cancer.

Скрыть анонс
07:52 News-Medical.NetColumbia researchers unravel why some glioblastomas respond to immunotherapy

Columbia researchers have learned why some glioblastomas--the most common type of brain cancer--respond to immunotherapy. The findings could help identify patients who are most likely to benefit from treatment with immunotherapy drugs and lead to the development of more broadly effective treatments.

Скрыть анонс
17.02.2019
01:46 CNN HealthImmunotherapies could change kidney cancer care, studies suggest

The way doctors typically approach kidney cancer treatment could be evolving.

Скрыть анонс
15.02.2019
18:04 FierceBiotech.comNovel immunotherapy prevents cervical, lung cancer in mice

Researchers at the University of Louisville were testing a protein-based molecule they originally developed to boost the power of T cells in treating cancer when they made a surprising discovery: The drug protected normal mice from developing cancer in the first place.

Скрыть анонс
12.02.2019
12:22 News-Medical.NetInhibiting tuberculosis-induced cell death with immunotherapy

Tuberculosis treatment still entails the intake several antibiotics over a period of many months and is torturous for many patients. The pathogen's increasing multidrug resistance additionally complicates this lengthy treatment, and side effects frequently lead to a discontinuation of treatment and high mortality rates.

Скрыть анонс
05:52 News-Medical.NetImmunotherapy drug can be effective in treating patients with recurrent brain tumors

A UCLA-led study suggests that for people with recurrent glioblastoma, administering an immunotherapy drug before surgery is more effective than using the drug afterward.

Скрыть анонс
11.02.2019
23:12 Google news HealthImmunotherapy may help patients with the kind of cancer that killed John McCain - Washington Post

Immunotherapy may help patients with the kind of cancer that killed John McCain  Washington Post Glioblastoma — the aggressive brain cancer that killed Sen. John McCain, Sen. Ted Kennedy and Beau Biden, son of Vice President Joe Biden — is among the ...
View full coverage on Google News

Скрыть анонс
23:12 Google news Sci/TechImmunotherapy may help patients with the kind of cancer that killed John McCain - Washington Post

Immunotherapy may help patients with the kind of cancer that killed John McCain  Washington Post Glioblastoma — the aggressive brain cancer that killed Sen. John McCain, Sen. Ted Kennedy and Beau Biden, son of Vice President Joe Biden — is among the ...
View full coverage on Google News

Скрыть анонс
11:18 News-Medical.NetImmunotherapy may be better than chemotherapy for Merkel cell carcinoma

The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with a rare but aggressive form of skin cancer known as Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy.

Скрыть анонс
08.02.2019
09:33 News-Medical.NetImmunotherapy drug found to be effective in patients with advanced Merkel cell carcinoma

A multi-center phase II clinical trial investigating pembrolizumab as a first-line and programmed cell death-1 therapy in patients with advanced Merkel cell carcinoma reports lasting tumor control, generally manageable side effects and improved overall survival.

Скрыть анонс
07.02.2019
22:37 ScienceDaily.comImmunotherapy appears better than chemotherapy for aggressive type of skin cancer

The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with a rare but aggressive form of skin cancer known as Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy.

Скрыть анонс
06.02.2019
20:08 ScienceDaily.comCombination treatment, diabetes drug and immunotherapy, may help to fight breast cancer

Researchers in Finland have discovered a drug combination that collaborates with the cancer cells' own MYC oncoprotein, which in large quantities causes self-destruction of the cancer cells. When this combination is enhanced with immune system-boosting anti-PD-1 therapy, a more effective and long-lasting therapeutic effect can be seen in mice. These findings pave the way for new treatment combination strategies to harness the body's natural defenses to fight cancer.

Скрыть анонс
05.02.2019
18:58 CancerNetwork.comEmerging Immunotherapy Approaches For Urothelial Cancer

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.

Скрыть анонс
18:46 Reuters.com HealthGSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.

Скрыть анонс
18:44 ReutersGSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.

Скрыть анонс
16:33 Reuters.com HealthMerck KGaA wins GSK for immunotherapy deal worth up to $4.2 billion

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.22 billion) to Germany's Merck KGaA for the rights to a novel immunotherapy.

Скрыть анонс
15:38 Reuters.com HealthMerck KGaA wins GSK for immunotherapy deal worth up to $4.2 billion

GlaxoSmithKline bolstered its cancer drug development pipeline, agreeing to pay up to 3.7 billion euros ($4.22 billion) to Germany's Merck KGaA for the rights to a novel immunotherapy.

Скрыть анонс
01:02 CancerNetwork.comEmerging Immunotherapy Approaches For Urothelial Cancer

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.

Скрыть анонс
30.01.2019
23:44 Technology.orgMachine Learning Finds Multiple Factors Underlie Cancer Immunotherapy Success

A University of Maryland-led research team is using a branch of artificial intelligence known as machine learning to

Скрыть анонс
28.01.2019
23:20 Nanowerk.comResearchers investigate coated Prussian blue nanoparticles for cancer immunotherapies

The researchers will work with Prussian blue nanoparticles (PBNPs) coated with immunological signals, used in combination with checkpoint inhibitors.

Скрыть анонс
23.01.2019
10:36 News-Medical.NetLudwig researchers find ways to make resistant melanomas susceptible to immunotherapy

A Ludwig Cancer Research study has uncovered a cellular mechanism by which melanomas that fail to respond to checkpoint blockade may be made susceptible to such immunotherapies.

Скрыть анонс
22.01.2019
23:53 CancerNetwork.comPerioperative Immunotherapy the Future of HCC Treatment?

Cancer Network spoke with Dr. Ahmed Kaseb about a phase II pilot trial of perioperative immunotherapy for resectable HCC and how the results could change future perioperative treatment of the disease.

Скрыть анонс
22:14 CancerNetwork.comCan an Immunotherapy Combo Improve Outcome in Refractory Colorectal Cancer?

Researchers tested whether the combination of durvalumab and tremelimumab could improve survival over best supportive care in patients with advanced refractory colorectal cancer.

Скрыть анонс
17.01.2019
20:02 CancerNetwork.comThe Emerging Profile of Immunotherapy Approaches in the Treatment of AML

Dr. Daver discusses immunotherapy approaches for patients with acute myeloid leukemia (AML), and his recent study results on the combination of azacitidine and nivolumab.

Скрыть анонс
19:29 CancerNetwork.comImmunotherapy Approaches in AML

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Скрыть анонс
16.01.2019
13:39 AzoNano.comResearchers Use DNA Origami to Enhance Effectiveness of Antibodies Used in Vaccines and Immunotherapy

Researchers from Karolinska Institutet, in collaboration with scientists at the University of Oslo, have used DNA origami—DNA-based design of precise nanostructures—and demonstrated the...

Скрыть анонс
09:23 News-Medical.NetMD Anderson Cancer Center collaborates with Dragonfly for new immunotherapy drug clinical trials

The University of Texas MD Anderson Cancer Center and Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly's TriNKET™ immunotherapy drug candidates to patients in clinical trials beginning in 2019.

Скрыть анонс
12.01.2019
07:21 News-Medical.NetNew potential immunotherapy target in pancreatic cancer identified

Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers.

Скрыть анонс
03:43 ScienceDaily.comVISTA checkpoint implicated in pancreatic cancer immunotherapy resistance

Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers.

Скрыть анонс
11.01.2019
21:32 CancerNetwork.comIs Patient Sex Associated With Immunotherapy Efficacy?

A meta-analysis looked at whether or not the sex of a patient had any association with the efficacy of immunotherapy in advanced cancers.

Скрыть анонс
04:21 ScienceDaily.comUncovering more options in cancer immunotherapy

If scientists want to boost immune cells' ability to kill cancer cells, then vast libraries of small molecules are potentially available. A new paper shows a platform to sort through them, plus validation. One of the hits: IAP antagonist birinapant, which is already in clinical trials (coincidentally).

Скрыть анонс
08.01.2019
12:41 NewYork TimesNonfiction: Could Immunotherapy Offer a Cure for Cancer?

In “The Breakthrough,” Charles Graeber recounts the long history of researchers’ attempts to mobilize the body’s immune system to fight disease.

Скрыть анонс
12:40 International Herald TribuneNonfiction: Could Immunotherapy Offer a Cure for Cancer?

In “The Breakthrough,” Charles Graeber recounts the long history of researchers’ attempts to mobilize the body’s immune system to fight disease.

Скрыть анонс
07.01.2019
23:14 NYT ScienceNonfiction: Could Immunotherapy Offer a Cure for Cancer?

In “The Breakthrough,” Charles Graeber recounts the long history of researchers’ attempts to mobilize the body’s immune system to fight disease.

Скрыть анонс
22:19 NYT HealthNonfiction: Could Immunotherapy Offer a Cure for Cancer?

In “The Breakthrough,” Charles Graeber recounts the long history of researchers’ attempts to mobilize the body’s immune system to fight disease.

Скрыть анонс
09:21 News-Medical.NetGE Healthcare and VUMC announce partnership to enable safer, more precise cancer immunotherapies

GE Healthcare and Vanderbilt University Medical Center today announced a five-year partnership to enable safer and more precise cancer immunotherapies. Multiple diagnostic tools will be developed to help predict both the efficacy of an immunotherapy treatment and its adverse effects for a specific patient before the therapy is administered.

Скрыть анонс
27.12.2018
11:42 Technology.orgYale Cancer Center scientists advise caution in immunotherapy research

In a new study by Yale Cancer Center (YCC), scientists suggest that as the number of clinical trials in cancer

Скрыть анонс
21.12.2018
14:51 Technology.orgFirst Oral Immunotherapy for Peanut Allergy Gets Closer to FDA Vote

After learning their son Andrew had a serious peanut allergy, Jennifer and Daniel Ayala did everything they could

Скрыть анонс
19.12.2018
11:26 Reuters.com HealthMolecular Partners agrees cancer immunotherapy deal with Amgen

Swiss biotechnology company Molecular Partners said it could earn more than $500 million in payments after striking a deal with U.S. drug giant Amgen to work together in cancer immunotherapy.

Скрыть анонс
18.12.2018
16:50 News-Medical.NetMetal-based chemotherapy enhances the effect of cancer immunotherapy

Due to their powerful tumor-killing effect, metal-based chemotherapies are frequently used in cancer treatment. However, it was hitherto assumed that they damaged the immune system, because of their cytotoxic (cell-damaging) effect even against dividing healthy cells.

Скрыть анонс
17.12.2018
18:44 CancerNetwork.comImmunotherapeutic Approaches to the Management of Head and Neck Cancer

Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.

Скрыть анонс
14.12.2018
09:48 News-Medical.NetNew findings could help develop new immunotherapies against cancer

NK cells, or natural killer cells, play an important role in the body's defences against cancer and various infections.

Скрыть анонс
12.12.2018
21:26 Nature.ComAdrenaline fuels a cytokine storm during immunotherapy

Скрыть анонс
11.12.2018
08:22 News-Medical.NetSlow-growing type of glioma may be vulnerable to immunotherapy, suggests study

Immunotherapy has proved effective in treating a number of cancers, but brain tumors have remained stubbornly resistant.

Скрыть анонс
10.12.2018
23:17 ScienceDaily.comSome brain tumors may respond to immunotherapy

A new study suggests that a slow-growing brain tumor arising in patients affected by neurofibromatosis type 1 (NF1) may be vulnerable to immunotherapy, which gives the immune system a boost in fighting cancer.

Скрыть анонс
07.12.2018
19:53 CancerNetwork.comNovel Immunotherapy for Primary Hemophagocytic Lymphohistiocytosis

Results of a study evaluating the safety and efficacy of a promising new agent were presented at ASH 2018.

Скрыть анонс
12:24 JapanTimes.co.jpNobel winner Tasuku Honjo sees bigger role for immunotherapy in battling cancer

Japanese scientist Tasuku Honjo, who jointly won this year’s Nobel Prize in physiology or medicine for his research on the immune system that contributed to ...

Скрыть анонс
05.12.2018
09:34 News-Medical.NetPhysician-scientists present updated efficacy data on CAR T-cell gene immunotherapy

Physician-scientists from Children's Hospital of Philadelphia presented updated efficacy and safety data on Kymriah--the first-ever U.S. Food and Drug Administration approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers at the 60th American Society of Hematology annual meeting, as well as first-of-its-kind research on overcoming CAR T-cell resistance.

Скрыть анонс
04.12.2018
11:17 Technology.orgStudy: Immunotherapy Better than Chemotherapy for Subtype of Head and Neck Cancer

A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San

Скрыть анонс
10:40 News-Medical.NetInternational study increases group of lung cancer patients who may benefit from immunotherapy

The strategy for triggering the patient's own immune system to attack cancer, immunotherapy, is proving effective for more and more tumor types, although to varying degrees.

Скрыть анонс
03.12.2018
22:46 ScienceDaily.comCombination immunotherapy shows high activity against recurrent Hodgkin lymphoma

A new combination of three drugs that harness the body's immune system is safe and effective, destroying most cancer cells in 95 percent of patients with recurrent Hodgkin lymphoma, according to new results.

Скрыть анонс
16:42 News-Medical.NetSSB enters into collaboration with Immunochina to develop new immunotherapy equipment

Sartorius Stedim Biotech, a leading international supplier of the biopharmaceutical industry, through its China affiliate, and Beijing-based Immunochina Pharmaceuticals, announced today that both parties have entered into a collaboration.

Скрыть анонс
30.11.2018
09:28 News-Medical.NetTriple combination cancer immunotherapy improves survival in mouse model of melanoma

Adoptive cell transfer is a promising cancer immunotherapy that involves isolating T cells from cancer patients that are capable of targeting their tumor, selecting the more active T cells and expanding those in the lab, and then transfusing them back into patients.

Скрыть анонс
00:53 ScienceDaily.comTriple combination cancer immunotherapy improves outcomes in preclinical melanoma model

In adoptive cell transfer immunotherapy, T cells able to recognize a tumor are harvested, expanded in the laboratory, and then reintroduced to attack the tumor. However, they often do not persist long enough to finish the job. A triple combination regimen of adoptive T cell transfer, a PIM kinase inhibitor, and a PD1 inhibitor improved T cell persistence and tumor control in a mouse model of melanoma, report investigators.

Скрыть анонс
28.11.2018
17:25 Medscape.ComParadox: Obesity Promotes Tumors but Boosts Immunotherapy

Obesity increases the risk for cancer, but, somewhat paradoxically, cancer patients who are obese and who undergo immunotherapy have better responses.

Скрыть анонс
26.11.2018
21:21 CancerNetwork.comEmerging Targets in Cancer Immunotherapy

Professor Lana E. Kandalaft, PharmD, PhD spoke with Cancer Network about the next generation of cancer immunotherapy.

Скрыть анонс
20:47 CancerNetwork.comDo Targeted Agents Aid Melanoma Immunotherapy?

Guy Ben-Betzalel, MD spoke with Cancer Network about the emerging role of targeted BRAF+MEK inhibition in antitumor immunity.

Скрыть анонс
22.11.2018
13:51 Technology.orgImmunotherapies linked to specific heart complications

In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that

Скрыть анонс
21.11.2018
16:41 Google news HealthDNA Immunotherapy Targets Two Pathologies in Alzheimer's Disease - PrecisionVaccinations

Скрыть анонс
20.11.2018
17:03 FierceBiotech.comStallergenes' allergy immunotherapy hits goal in phase 3

A phase 3 trial of Stallergenes Greer’s treatment for house dust mite-induced allergic rhinitis has met its primary endpoint. The late-phase success sets Stallergenes up to file for FDA approval of oral immunotherapy STAGR320.

Скрыть анонс
09:54 Technology.orgNew immunotherapy improves MS symptoms

A world-first clinical trial of a new cellular immunotherapy for multiple sclerosis (MS) has improved symptoms and quality

Скрыть анонс
19.11.2018
16:46 Medscape.ComImmunotherapy Adverse Events More Common Than Initially Reported

The rate of immunotherapy adverse events, as evidenced in real world data, is much higher than was previously reported in the pivotal clinical trials of these agents.

Скрыть анонс
15.11.2018
19:58 CancerNetwork.comWhat Immunotherapy Combination Is Best in Metastatic Bladder Cancer?

Extended follow-up from the CheckMate 032 trial showed strong results with three different immunotherapy regimens involving nivolumab and ipilimumab in patients with previously treated metastatic urothelial carcinoma.

Скрыть анонс
19:09 News-Medical.NetCRISPR-based tool shown to enhance cell-based immunotherapy

Researchers have developed a CRISPR-based tool called SLICE that can boost the effectiveness of immune cell therapies.

Скрыть анонс
14.11.2018
22:01 Medscape.ComFecal Transplant May Resolve Immunotherapy-Related Colitis

Colitis associated with the use of checkpoint inhibitors may be managed successfully by fecal microbiota transplant, says a team reporting results in two patients.

Скрыть анонс
00:46 CancerNetwork.comCan Immunotherapy Be Effective in Certain NETs Patients?

In general, NETs are considered an “immunological desert,” but a new study showed some promise for immunotherapy.

Скрыть анонс
13.11.2018
14:16 FightAging.OrgA Popular Science View of Checkpoint Inhibitor Cancer Immunotherapies

Checkpoint inhibitor therapies are a demonstrably successful approach to cancer immunotherapy. They suppress a mechanism that normally restrains immune cells from attacking other cells. This mechanism is abused by cancers, alongside a variety of other ways in which the immune system can be subverted or quieted. Any advanced tumor tends to have evolved into a state in which it is ignored or even helped by the immune system. Checkpoint inhibitor therapies are an improvement on chemotherapy when it comes to the trade-off between harming the cancer and harming the patient, as well as in the odds of success, but still present risks to patients. Immune checkpoints exist to prevent autoimmunity, and rampant autoimmunity can be just as deadly as any cancer. Our usual defence against […]

Скрыть анонс
09:04 News-Medical.NetStudy finds why obesity both fuels cancer growth and helps immunotherapy kill tumors

A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors.

Скрыть анонс
03:44 Gizmag How can obesity both fuel tumor growth and help new immunotherapy drugs work better?


Two new studies have provided compelling insights into the relationship between obesity and cancer. The research reveals fascinatingly paradoxical effects, suggesting obesity can suppress our immune responses to enhance tumor growth, but also improve the efficacy of a new kind of cancer-killing immunotherapy.
.. Continue Reading How can obesity both fuel tumor growth and help new immunotherapy drugs work better? Category: Medical Tags: Cancer Immunotherapy Obesity

Скрыть анонс
12.11.2018
15:09 KoreaTimes.co.krLG Chem to develop cancer immunotherapy drugs

LG Chem has joined forces with U.S.-based pharmaceutical firm Cue Biopharma to develop cancer immunotherapy drugs, the company said Monday

Скрыть анонс
09.11.2018
13:27 Technology.orgNew immunotherapy technique can specifically target tumor cells, UCI study reports

A new immunotherapy screening prototype developed by University of California, Irvine researchers can quickly create individualized cancer treatments

Скрыть анонс
08.11.2018
22:55 CancerNetwork.comStudy Sheds Light on Risk of Liver Injury in Combined Immunotherapy

The frequency of hepatotoxic immune-related adverse events varied in patients receiving one vs multiple chemotherapy agents.

Скрыть анонс
19:52 ScienceDaily.comCombination chemotherapy and immunotherapy effective in Phase II leukemia study

A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia, according to new findings.

Скрыть анонс
First← Previous12345678910Previous →Last